DRG Market Assessment 보고서

IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…

ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute…

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS…

MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional DMARDs, such as methotrexate. For  RA patients who are refractory to conventional…

MARKET OUTLOOK The moderate to severe Crohn’s disease (CD) therapy market presents an attractive commercial opportunity for new, effective treatments. Tumor necrosis factor-alpha (TNF-α)…

Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body, and its symptoms range from general malaise to serious, CNS and renal manifestations…

Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for…

Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (…

AS is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness…

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and…

Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (sUA). Treatment of the painful acute flares is distinct from the chronic management of…